SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Opioid Use Disorder 
Treatment Expansion and Modernization Act’’. 
SEC. 2. FINDING. 
The Congress finds that opioid use disorder has be-
come a public health epidemic that must be addressed by 
increasing awareness and access to all treatment options 
for opioid use disorder, overdose reversal, and relapse pre-
vention. 
SEC. 3. OPIOID USE DISORDER TREATMENT MODERNIZA-
TION. 
(a) IN GENERAL.—Section 303(g)(2) of the Con-
trolled Substances Act (21 U.S.C. 823(g)(2)) is amend-
ed— 
(1) in subparagraph (B), by striking clauses (i), 
(ii), and (iii) and inserting the following: 
‘‘(i) The practitioner is a qualifying practitioner 
(as defined in subparagraph (G)). 
‘‘(ii) With respect to patients to whom the prac-
titioner will provide such drugs or combinations of 
drugs, the practitioner has the capacity to provide 
directly, by referral, or in such other manner as de-
termined by the Secretary— 
‘‘(I) all schedule III, IV, and V drugs, as 
well as unscheduled medications approved by 
the Food and Drug Administration, for the
treatment of opioid use disorder, including such 
drugs and medications for maintenance, detoxi-
fication, overdose reversal, and relapse preven-
tion, as available; and 
‘‘(II) appropriate counseling and other ap-
propriate ancillary services. 
‘‘(iii)(I) The total number of such patients of 
the practitioner at any one time will not exceed the 
applicable number. Except as provided in subclause 
(II), the applicable number is 30. 
‘‘(II) The applicable number is 100 if, not soon-
er than 1 year after the date on which the practi-
tioner submitted the initial notification, the practi-
tioner submits a second notification to the Secretary 
of the need and intent of the practitioner to treat up 
to 100 patients. 
‘‘(III) The Secretary may by regulation change 
such total number. 
‘‘(IV) The Secretary may exclude from the ap-
plicable number patients to whom such drugs or 
combinations of drugs are directly administered by 
the qualifying practitioner in the office setting. 
‘‘(iv) If the Secretary by regulation increases 
the total number of patients which a qualifying prac-
titioner is permitted to treat pursuant to clause
(iii)(II), the Secretary shall require such a practi-
tioner to obtain a written agreement from each pa-
tient, including the patient’s signature, that the pa-
tient— 
‘‘(I) will receive an initial assessment and 
treatment plan and periodic assessments and 
treatment plans thereafter; 
‘‘(II) will be subject to medication adher-
ence and substance use monitoring; 
‘‘(III) understands available treatment op-
tions, including all drugs approved by the Food 
and Drug Administration for the treatment of 
opioid use disorder, including their potential 
risks and benefits; and 
‘‘(IV) understands that receiving regular 
counseling services is critical to recovery. 
‘‘(v) The practitioner will comply with the re-
porting requirements of subparagraph (D)(i)(IV).’’; 
(2) in subparagraph (D)— 
(A) in clause (i), by adding at the end the 
following: 
‘‘(IV) The practitioner reports to the Secretary, 
at such times and in such manner as specified by 
the Secretary, such information and assurances as 
the Secretary determines necessary to assess wheth-
er the practitioner continues to meet the require-
ments for a waiver under this paragraph.’’; 
(B) in clause (ii), by striking ‘‘Upon re-
ceiving a notification under subparagraph (B)’’ 
and inserting ‘‘Upon receiving a determination 
from the Secretary under clause (iii) finding 
that a practitioner meets all requirements for a 
waiver under subparagraph (B)’’; and 
(C) in clause (iii)— 
(i) by inserting ‘‘and shall forward 
such determination to the Attorney Gen-
eral’’ before the period at the end of the 
first sentence; and 
(ii) by striking ‘‘physician’’ and in-
serting ‘‘practitioner’’; 
(3) in subparagraph (G)— 
(A) by amending clause (ii)(IV) to read as 
follows: 
‘‘(IV) The physician has, with respect to 
the treatment and management of opiate-de-
pendent patients, completed not less than 8 
hours of training (through classroom situations, 
seminars at professional society meetings, elec-
tronic communications, or otherwise) that is 
provided by the American Society of Addiction
Medicine, the American Academy of Addiction 
Psychiatry, the American Medical Association, 
the American Osteopathic Association, the 
American Psychiatric Association, or any other 
organization that the Secretary determines is 
appropriate for purposes of this subclause. Such 
training shall address— 
‘‘(aa) opioid maintenance and detoxi-
fication; 
‘‘(bb) appropriate clinical use of all 
drugs approved by the Food and Drug Ad-
ministration for the treatment of opioid 
use disorder; 
‘‘(cc) initial and periodic patient as-
sessments (including substance use moni-
toring); 
‘‘(dd) individualized treatment plan-
ning; overdose reversal; relapse prevention; 
‘‘(ee) counseling and recovery support 
services; 
‘‘(ff) staffing roles and considerations; 
‘‘(gg) diversion control; and 
‘‘(hh) other best practices, as identi-
fied by the Secretary.’’; and 
(B) by adding at the end the following:
‘‘(iii) 
The 
term 
‘qualifying 
practitioner’ 
means— 
‘‘(I) a qualifying physician, as defined in 
clause (ii); or 
‘‘(II) during the period beginning on the 
date of the enactment of the Opioid Use Dis-
order Treatment Expansion and Modernization 
Act and ending on the date that is 3 years after 
such date of enactment, a qualifying other prac-
titioner, as defined in clause (iv). 
‘‘(iv) The term ‘qualifying other practitioner’ 
means a nurse practitioner or physician assistant 
who satisfies each of the following: 
‘‘(I) The nurse practitioner or physician 
assistant is licensed under State law to pre-
scribe schedule III, IV, or V medications for the 
treatment of pain. 
‘‘(II) The nurse practitioner or physician 
assistant satisfies one or more of the following: 
‘‘(aa) Has completed not fewer than 
24 hours of initial training addressing each 
of the topics listed in clause (ii)(IV) 
(through classroom situations, seminars at 
professional society meetings, electronic 
communications, or otherwise) provided by